

## Adaptation of DE-GSK and addition of AT GSK

- Adaptation of the DE GSK and addition of the AT GSK are welcome.
- However, the impact study shows important variations of the impact of those changes on prices and on welfare results.
- Such variations are unclear to market participants.
- Market parties would welcome further information on those impacts and suggest:
  - Extension of the parallel run study for a longer period than 10 days
  - Publish clear descriptions of the methodologies used for computing the different GSKs and improve transparency
  - Regulatory approval of GSK changes